• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Bausch + Lomb, Novaliq Receive FDA Approval for Dry Eye Disease Treatment

Article

Miebo reported as the first cleared remedy that directly targets tear evaporation.

Augentropfen. Image Credit: Adobe Stock Images/frankenphoto

Image Credit: Adobe Stock Images/frankenphoto

Bausch + Lomb, a global eye care company, and Novaliq, a biopharmaceutical company, have officially announced that the FDA has approved Miebo, a treatment for dry eye disease. Reportedly, the medication is the first and only FDA-approved treatment that directly targets tear evaporation.

“Today’s FDA approval of MIEBO further advances dry eye disease treatment by addressing a significant unmet need for millions of people suffering with this disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of dry eye disease that directly targets evaporation. We expect to make MIEBO commercially available in the second half of this year.”

Recent Videos
Related Content